United States, Dec. 19 -- The U.S. Food and Drug Administration today awarded national priority vouchers under the Commissioner's National Priority Voucher (CNPV) pilot program to two investigational products for their potential to increase access through affordability for American patients.The products are:Enlicitide decanoate - an oral PCSK9 inhibitor for lowering LDL cholesterolSacituzumab Tirumotecan - a trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate With these awards,18 products have now received a voucher under the CNPV pilot program since it was established in June 2025. On December 9, the agency announced its first review decision under the program, achieving significant time savings compared to a typica...